Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -4.7x - -5.2x | -5.0x |
| Selected Fwd P/E Multiple | -3.9x - -4.3x | -4.1x |
| Fair Value | $3.60 - $3.98 | $3.79 |
| Upside | 17.7% - 30.1% | 23.9% |
| Benchmarks | - | Full Ticker |
| Veracyte, Inc. | - | NasdaqGM:VCYT |
| Exact Sciences Corporation | - | NasdaqCM:EXAS |
| Personalis, Inc. | - | NasdaqGM:PSNL |
| Trevena, Inc. | - | OTCPK:TRVN |
| Celldex Therapeutics, Inc. | - | NasdaqCM:CLDX |
| Cardiff Oncology, Inc. | - | NasdaqCM:CRDF |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| VCYT | EXAS | PSNL | TRVN | CLDX | CRDF | |||
| NasdaqGM:VCYT | NasdaqCM:EXAS | NasdaqGM:PSNL | OTCPK:TRVN | NasdaqCM:CLDX | NasdaqCM:CRDF | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 132.4% | -404.0% | 24.9% | -10.6% | -11.6% | -9.6% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -21.0% | -27.4% | -102.7% | -19680.3% | -2846.3% | -7594.3% | ||
| Prior Fiscal Year | -20.6% | -8.2% | -147.4% | 12839.7% | -2054.8% | -8496.9% | ||
| Latest Fiscal Year | 5.4% | -37.3% | -96.1% | -1289.2% | -2248.8% | -6655.2% | ||
| Latest Twelve Months | 5.4% | -37.3% | -96.1% | -6233.7% | -2248.8% | -6655.2% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 41.1x | 329.6x | -2.9x | -0.8x | -2.1x | -2.3x | ||
| Price / LTM Sales | 5.2x | 2.9x | 3.6x | 2.0x | 159.3x | 298.0x | ||
| LTM P/E Ratio | 95.5x | -7.8x | -3.7x | 0.0x | -7.1x | -4.5x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -7.8x | -3.7x | 95.5x | |||||
| Historical LTM P/E Ratio | -31.4x | -4.5x | -1.6x | |||||
| Selected P/E Multiple | -4.7x | -5.0x | -5.2x | |||||
| (x) LTM Net Income | (45) | (45) | (45) | |||||
| (=) Equity Value | 214 | 225 | 237 | |||||
| (/) Shares Outstanding | 66.5 | 66.5 | 66.5 | |||||
| Implied Value Range | 3.22 | 3.39 | 3.56 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 3.22 | 3.39 | 3.56 | 3.06 | ||||
| Upside / (Downside) | 5.2% | 10.7% | 16.3% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | VCYT | EXAS | PSNL | TRVN | CLDX | CRDF | |
| Value of Common Equity | 2,304 | 8,071 | 305 | 1 | 1,119 | 204 | |
| (/) Shares Outstanding | 77.9 | 185.8 | 88.3 | 0.9 | 66.4 | 66.5 | |
| Implied Stock Price | 29.56 | 43.45 | 3.45 | 1.29 | 16.85 | 3.06 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 29.56 | 43.45 | 3.45 | 1.29 | 16.85 | 3.06 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |